Healthcare Provider Preferences for Attributes of Influenza Vaccines in the United States: Results From a Discrete-Choice Experiment Study

Speaker(s)

Poulos C1, McMichael A2, Kent C1, Rudin D3, Buck P3, Ghaswalla P3, Mehta D3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Belfast, UK, 3Moderna, Inc., Cambridge, MA, USA

Presentation Documents

OBJECTIVES: To quantify preferences for influenza vaccine attributes among healthcare providers (HCPs) in the United States (US).

METHODS: Using a discrete-choice experiment (DCE), US HCPs were presented with a series of experimentally-designed pairs of hypothetical influenza vaccines comprising five attributes with varying levels: absolute vaccine efficacy (AVE) (15%-60% of influenza infections prevented), hospitalization prevention (same as most other vaccines, more than most other vaccines), durability (protection fades within 6 months, constant protection for at least 6 months), and side effects (risk of moderate-to-severe injection site reactions [ISR] [0%-50%] and risk of flu-like symptoms [FLS] due to the vaccine [0%-60%]). In each choice question, respondents selected their preferred vaccine or “no flu vaccine” for one of two patients described in vignettes. Random-parameters logit analysis results were used to calculate conditional relative attribute importance (CRI) out of 100% and maximum acceptable risks of vaccine side effects in exchange for improvements in vaccine efficacy.

RESULTS: The sample included 299 US HCPs (144 physicians and 5 physician assistants [primary care, internal medicine, family medicine, general practice, or geriatrics]), 150 pharmacists [all practice settings]). Respondents preferred either influenza vaccine over no vaccine in 95.3% of DCE questions. HCPs placed greatest importance on avoiding risk of FLS (CRI, 39.8%) and increasing AVE (CRI, 37.4%), followed by avoiding ISR risk (CRI, 14.1%). Durability (CRI, 5.1%) and hospitalization prevention (CRI, 3.5%) were least important. For an improvement in AVE from 15% to 25%, HCPs were willing to accept a 44.7% risk of ISR or a 21% risk of FLS. For an improvement in AVE from 25% to 50%, HCPs were willing to accept > 50% risk of ISR or a 26.8% risk of FLS.

CONCLUSIONS: HCPs in the US were more likely to accept increases in vaccine-related risks of FLS than ISR in exchange for improved AVE.

Code

PCR228

Topic

Patient-Centered Research

Topic Subcategory

Stated Preference & Patient Satisfaction

Disease

Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines